Evidence from models of neurodegenerative diseases indicates that CH can stimulate positive immune responses in addition to cancer immunotherapy; CHIP carriers showed improved outcomes in Alzheimer’s disease and increased microglial activation, suggesting a possible protective role in neuroinflammation (133, 134). This evidence concerns the gene STUB1 and cancer.